Philip Vorwald has been appointed vice president and general manager of Celsis International’s In Vitro Technologies (Celsis IVT) division. He will be responsible for setting and overseeing the long-term growth strategy of the company’s ADME-Tox products, which include fresh and cryopreserved cells, enzymes and other media produced for drug development. He will report to Jay LeCoque, Celsis International’s chief executive officer. “Philip’s extensive life scie...